Detrusitol

Detrusitol

tolterodine

Manufacturer:

Pfizer
Concise Prescribing Info
Contents
Tolterodine l-tartrate
Indications/Uses
Overactive bladder w/ symptoms of urinary urgency, frequency or urge incontinence.
Dosage/Direction for Use
2 mg twice daily. Dose may be reduced from 2 mg to 1 mg twice daily. Renal & hepatic impairment & in patient receiving concomitant ketoconazole or other potent CYP3A4 inhibitors Recommended total daily dose: 2 mg (ie, tolterodine tab 1 mg twice daily). After 6 mth, the need for further treatment should be considered.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis, toxic megacolon.
Special Precautions
Significant bladder outlet obstruction at risk for urinary retention, GI obstructive disorders eg, pyloric stenosis. Autonomic neuropathy, hiatus hernia, organic reason for urgency & frequency should be considered before treatment. Myasthenia gravis. Congenital or documented acquired QT prolongation. Patients who are taking class IA (eg, quinidine, procainamide) or class III (eg, amiodarone, sotalol) antiarrhythmic medications. Concomitant medication w/ potent CYP3A4 inhibitors, eg, macrolide antibiotics (erythromycin & clarithromycin) or antifungal agents (ketoconazole, itraconazole & miconazole). Renal or hepatic disease. May affect ability to drive or operate machinery. Women of fertile age should use adequate contraception. Pregnancy & lactation. Childn.
Adverse Reactions
Dry mouth, dyspepsia, reduced lacrimation; bronchitis; allergic reactions; confusion; dizziness, headache, somnolence; abnormal vision (including abnormal accommodation), dry eyes; vertigo; flushed skin; abdominal pain, constipation, flatulence, gastroesophageal reflux; dry skin; dysuria, urinary retention; chest pain, fatigue; increased wt; anaphylactoid reactions; disorientation, hallucinations; memory impairment; tachycardia, palpitations; diarrhea; angioedema; peripheral edema.
Drug Interactions
Other drugs w/ antimuscarinic properties may result in more pronounced therapeutic & adverse effect. Concomitant administration w/ muscarinic receptor agonists may reduce therapeutic effect of Detrusitol. The effect of prokinetics eg, metoclopramide & cisapride on GI tract (increased lower esophageal sphincter pressure & improved gastroduodenal coordination) may be decreased by Detrusitol. Increased plasma conc w/ ketoconazole.
MIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04BD07 - tolterodine ; Belongs to the class of urinary antispasmodics.
Presentation/Packing
Form
Detrusitol FC tab 2 mg
Packing/Price
2 × 14's (Rp506,042/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in